Evidence map›Paper›PMID 41563562›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026

Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902).

Shunji Endo, Ryo Tanaka, Toshifumi Yamaguchi, Hiromichi Miyagaki, Junji Kawada, Takeshi Omori, Naoki Takahashi, Toru Masuzawa, Haruna Furukawa, Yuya Sato and 9 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Shunji EndoDepartment of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan.ORCID 0000-0003-0720-4156
Ryo TanakaDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Toshifumi YamaguchiCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan. yamagu.toshifumi@gmail.com.
Hiromichi MiyagakiDepartment of Surgery, Osaka Rosai Hospital, Sakai, Japan.
Junji KawadaDepartment of Surgery, Yao Municipal Hospital, Yao, Japan.
Takeshi OmoriDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Naoki TakahashiDepartment of Gastroenterology, Saitama Prefectural Cancer Center, Saitama, Japan.
Toru MasuzawaDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Haruna FurukawaDepartment of Gastroenterological Surgery, Rinku General Medical Center, Izumisano, Japan.
Yuya SatoDepartment of Gastrointestinal Surgery, Institute of Science Tokyo Hospital, Tokyo, Japan.
Atsushi TakenoDepartment of Surgery, NHO Osaka National Hospital, Osaka, Japan.
Naoki ShinnoDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Ryohei KawabataDepartment of Surgery, Osaka Rosai Hospital, Sakai, Japan.
Shinsuke KatsuyamaDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Shigeyoshi HigashiDepartment of Gastroenterological Surgery, Rinku General Medical Center, Izumisano, Japan.
Yukinori KurokawaDepartment of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, Suita, Japan.
Toshimasa TsujinakaIzumi City General Hospital, Izumi, Japan.
Toshio ShimokawaDepartment of Biostatistics, Faculty of Medicine, Wakayama Medical University, Wakayama, Japan.
Taroh SatohCenter for Cancer Genomics and Precision Medicine, The University of Osaka Hospital, Suita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLarge type 3 (≥ 8 cm) and type 4 gastric cancers are associated with extremely poor prognoses. The phase III JCOG0501 trial, which evaluated neoadjuvant S-1 plus cisplatin, failed to demonstrate any survival benefits. Docetaxel, oxaliplatin, and S-1 (DOS) have been explored as more effective perioperative regimens for these tumors.

methodsEligible patients had large type 3 or type 4 gastric cancer without distant metastases, except for positive peritoneal cytology (CY). Patients received three cycles of neoadjuvant DOS (docetaxel 40 mg/m

resultsOf the 48 patients enrolled, 27 had type 4 tumors (56.2%), and 10 (20.8%) had CY1. Overall, 91.7% of patients completed neoadjuvant DOS. R0 resection rate was achieved in 89.6% of patients, a pathological response grade ≥ 1b in 66.7%, and negative CY conversion in 80.0%. The 3-year PFS rate was 37.5% (95% confidence interval [CI], 24.1-50.6%; 80% CI 28.6-46.4%; p = 0.960), and the 3-year overall survival rate was 52.1% (95% CI 37.2-65.0%).

conclusionsAlthough neoadjuvant DOS therapy demonstrated favorable pathological responses, the 3-year PFS did not exceed the predefined threshold, and a survival benefit was not demonstrated.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyStomach NeoplasmsAdultAgedDocetaxelDrug CombinationsFemaleGastrectomyHumansMaleMiddle AgedOxaliplatinOxonic AcidPrognosisSurvival RateDocetaxelDrug CombinationsOxaliplatinOxonic AcidS 1 (combination)TegafurDocetaxelLinitis plasticaNeoadjuvant therapyOxaliplatinS-1Stomach neoplasms

Identifiers

PMID41563562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.